Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Year: 2015
Type: review
Abstract: Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Source: Leukemia
DOI: 10.1038/leu.2015.29
Institutions: Salisbury District Hospital, University of Southampton, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Lund University, Imperial College London, University of Turin, Leipzig University, Medical University of Vienna, Institute of Haematology and Blood Transfusion, Université de Bordeaux, Inserm, Centre Hospitalier Universitaire de Bordeaux, University of Bologna, University Hospital of Bern, Vejle Sygehus, Karolinska Institutet, Jagiellonian University, Carol Davila University of Medicine and Pharmacy, Institutul Clinic Fundeni, Federico II University Hospital, University of Naples Federico II, CEINGE Biotecnologie Avanzate Franco Salvatore (Italy), University Medical Centre Mannheim, Jena University Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W2077812841
